| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P Homan, A Neumeister, A C Nugent, D S Charney, W C Drevets, G Hasle. Serotonin versus catecholamine deficiency: behavioral and neural effects of experimental depletion in remitted depression. Translational psychiatry. vol 5. 2016-01-20. PMID:25781231. |
the aim of this study was to elucidate the differential symptomatology and neurophysiology in response to reductions in serotonergic versus catecholaminergic neurotransmission in subjects at high risk of depression recurrence. |
2016-01-20 |
2023-08-13 |
human |
| Sarah G Helton, Falk W Lohof. Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics. vol 16. issue 5. 2016-01-19. PMID:25916524. |
most antidepressant drugs for the treatment of depression and anxiety disorders have effects on the serotonergic neurotransmitter system; thus, genetic polymorphisms in the genes involved in this pathway represent logical candidates for investigation. |
2016-01-19 |
2023-08-13 |
Not clear |
| Kathleen Biard, Alan B Douglass, Rébecca Robillard, Joseph De Koninc. A pilot study of serotonin-1A receptor genotypes and rapid eye movement sleep sensitivity to serotonergic/cholinergic imbalance in humans: a pharmacological model of depression. Nature and science of sleep. vol 8. 2015-12-31. PMID:26719734. |
we previously reported that cholinergic and serotonergic agents induce sleep changes partially consistent with monoamine models of sleep disturbances in depression. |
2015-12-31 |
2023-08-13 |
Not clear |
| Visakh Prabhakar, Deepali Gupta, Prateek Kanade, Mahesh Radhakrishna. Diabetes-associated depression: the serotonergic system as a novel multifunctional target. Indian journal of pharmacology. vol 47. issue 1. 2015-12-22. PMID:25821303. |
diabetes-associated depression: the serotonergic system as a novel multifunctional target. |
2015-12-22 |
2023-08-13 |
Not clear |
| Victor B Feni. Revisiting Antagonist Effects in Hypoglossal Nucleus: Brainstem Circuit for the State-Dependent Control of Hypoglossal Motoneurons: A Hypothesis. Frontiers in neurology. vol 6. 2015-12-09. PMID:26648908. |
we reassessed and provided new insights into the findings that were obtained in our previous experiments that employed the injections of combined adrenergic, serotonergic, gabaergic, and glycinergic antagonists into the hypoglossal nucleus in order to pharmacologically abolish the depression of hypoglossal nerve activity that occurred during carbachol-induced rapid-eye-movement (rem) sleep-like state in anesthetized rats. |
2015-12-09 |
2023-08-13 |
rat |
| Victor B Feni. Revisiting Antagonist Effects in Hypoglossal Nucleus: Brainstem Circuit for the State-Dependent Control of Hypoglossal Motoneurons: A Hypothesis. Frontiers in neurology. vol 6. 2015-12-09. PMID:26648908. |
we concluded that noradrenergic disfacilitation is the major mechanism that is responsible for approximately 90% of the depression of hypoglossal motoneurons, whereas the remaining 10% can be explained by serotonergic mechanisms that have net inhibitory effect on hypoglossal nerve activity during rem sleep-like state. |
2015-12-09 |
2023-08-13 |
rat |
| Paul W Andrews, Aadil Bharwani, Kyuwon R Lee, Molly Fox, J Anderson Thomso. Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neuroscience and biobehavioral reviews. vol 51. 2015-12-01. PMID:25625874. |
the evolution of the serotonergic system and its role in depression and the antidepressant response. |
2015-12-01 |
2023-08-13 |
Not clear |
| Daniela Zahn, Frank Petrak, Leonora Franke, Anna-Karolina Hägele, Georg Juckel, Florian Lederbogen, Horst Neubauer, Christine Norra, Idun Uhl, Stephan Herpert. Cortisol, platelet serotonin content, and platelet activity in patients with major depression and type 2 diabetes: an exploratory investigation. Psychosomatic medicine. vol 77. issue 2. 2015-11-20. PMID:25626989. |
hypothalamic-pituitary-adrenal system dysfunction, serotonergic system alterations, and enhanced platelet activity may contribute to the increased cardiac risk in depression. |
2015-11-20 |
2023-08-13 |
Not clear |
| Andrea Devera, Claudia Pascovich, Patricia Lagos, Atilio Falconi, Sharon Sampogna, Michael H Chase, Pablo Torterol. Melanin-concentrating hormone (MCH) modulates the activity of dorsal raphe neurons. Brain research. vol 1598. 2015-11-17. PMID:25541366. |
serotonergic neurons of the drn are involved in the control of sleep and play a critical role in major depression. |
2015-11-17 |
2023-08-13 |
rat |
| Ana Ching-López, Jorge Cervilla, Margarita Rivera, Esther Molina, Kathryn McKenney, Isabel Ruiz-Perez, Miguel Rodríguez-Barranco, Blanca Gutiérre. Epidemiological support for genetic variability at hypothalamic-pituitary-adrenal axis and serotonergic system as risk factors for major depression. Neuropsychiatric disease and treatment. vol 11. 2015-11-06. PMID:26543368. |
epidemiological support for genetic variability at hypothalamic-pituitary-adrenal axis and serotonergic system as risk factors for major depression. |
2015-11-06 |
2023-08-13 |
Not clear |
| Jana Haase, Eric Brow. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression--a central role for the serotonin transporter? Pharmacology & therapeutics. vol 147. 2015-10-26. PMID:25444754. |
monoamine, in particular serotonergic neurotransmission has long been recognized as an important factor in the aetiology of depression. |
2015-10-26 |
2023-08-13 |
Not clear |
| Yeshwant Kurhe, Mahesh Radhakrishnan, Deepali Gupt. Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests. Metabolic brain disease. vol 29. issue 3. 2015-10-16. PMID:24964970. |
ondansetron through allosteric modulation of serotonergic system elevates the serotonin level and thereby regulates the insulin secretion and hence, reversing the "altered glucose level", could be the possible antidepressive-like mechanism against depression co-morbid with obesity. |
2015-10-16 |
2023-08-13 |
mouse |
| Eryan Kong, Sonja Sucic, Francisco J Monje, Giorgia Savalli, Weifei Diao, Deeba Khan, Marianne Ronovsky, Maureen Cabatic, Florian Koban, Michael Freissmuth, Daniela D Polla. STAT3 controls IL6-dependent regulation of serotonin transporter function and depression-like behavior. Scientific reports. vol 5. 2015-10-16. PMID:25760924. |
here we tested the hypothesis that il6-induced modulation of serotonergic neurotransmission through the stat3 signaling pathway contributes to the role of il6 in depression. |
2015-10-16 |
2023-08-13 |
mouse |
| Leah R Brooks, Heide L Pals, Courtney L Enix, Rachel A Woolaver, Evan D Paul, Christopher A Lowry, Pei-San Tsa. Fibroblast growth factor 8 deficiency compromises the functional response of the serotonergic system to stress. PloS one. vol 9. issue 7. 2015-10-14. PMID:24992493. |
functionally heterogeneous populations of serotonergic neurons, located within the dorsal raphe nucleus (dr), play a role in stress-related behaviors and neuropsychiatric illnesses such as anxiety and depression. |
2015-10-14 |
2023-08-13 |
mouse |
| Peter Meerlo, Robbert Havekes, Axel Steige. Chronically restricted or disrupted sleep as a causal factor in the development of depression. Current topics in behavioral neurosciences. vol 25. 2015-10-09. PMID:25646723. |
the mechanisms through which insufficient sleep increases the risk for depression are poorly understood but may include effects of sleep disturbance on neuroendocrine stress systems, serotonergic neurotransmission, and various interacting signaling pathways involved in the regulation of neuronal plasticity and neurogenesis. |
2015-10-09 |
2023-08-13 |
Not clear |
| K E Tansey, J J H Rucker, D H Kavanagh, M Guipponi, N Perroud, G Bondolfi, E Domenici, D M Evans, J Hauser, N Henigsberg, B Jerman, W Maier, O Mors, M O'Donovan, T J Peters, A Placentino, M Rietschel, D Souery, K J Aitchison, I Craig, A Farmer, J R Wendland, A Malafosse, G Lewis, S Kapur, P McGuffin, R Uhe. Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. The pharmacogenomics journal. vol 14. issue 4. 2015-10-08. PMID:24445990. |
cnv data were available for 1565 individuals with mdd from the newmeds (novel methods leading to new medications in depression and schizophrenia) consortium with prospective data on treatment outcome with either a serotonergic or noradrenergic antidepressant. |
2015-10-08 |
2023-08-12 |
Not clear |
| Ahmad A Khundakar, Alan J Thoma. Neuropathology of depression in Alzheimer's disease: current knowledge and the potential for new treatments. Journal of Alzheimer's disease : JAD. vol 44. issue 1. 2015-09-10. PMID:25208623. |
postmortem studies have also suggested that depression in dementia does not arise from serotonergic or noradrenergic abnormalities, or indeed from the degenerative pathology associated with alzheimer's disease. |
2015-09-10 |
2023-08-13 |
Not clear |
| Lara-Jane Kepser, Judith R Homber. The neurodevelopmental effects of serotonin: a behavioural perspective. Behavioural brain research. vol 277. 2015-09-08. PMID:24859172. |
serotonin is well known for its role in psychiatric disorders like depression and autism, but it is less clear how aberrant behaviour associated with these disorders are shaped by serotonergic alterations during prenatal and postnatal development. |
2015-09-08 |
2023-08-13 |
Not clear |
| Deepali Gupta, Mahesh Radhakrishnan, Yeshwant Kurh. Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. European journal of pharmacology. vol 744. 2015-08-07. PMID:25284215. |
ondansetron, a 5ht3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. |
2015-08-07 |
2023-08-13 |
mouse |
| Deepali Gupta, Mahesh Radhakrishnan, Yeshwant Kurh. Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. European journal of pharmacology. vol 744. 2015-08-07. PMID:25284215. |
collectively, the data indicate that ondansetron may reverse depression and anxiety-like behavioral deficits associated with diabetes in mice and modulation of serotonergic activity may be a key mechanism of the compound. |
2015-08-07 |
2023-08-13 |
mouse |